Bioactivity:

DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit.

CAS nr:

1020172-07-9

Purity:

98%

Molecular Weight:

553,59

SMILES:

CNC(=O)c1nccc(Oc2cc(F)c(NC(=O)Nc3cc(nn3c3cc4c(cc3)nccc4)C(C)(C)C)cc2)c1

Formula:

C30H28FN7O3

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Tyrosine Kinase/Adaptors,Angiogenesis,Apoptosis,Angiogenesis,Tyrosine Kinase/Adaptors,Cytoskeletal Signaling

Target:

FLT,FLT,Src,Src,Apoptosis,Bcr-Abl,Bcr-Abl,Bcr-Abl